Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

1.310 +0.080 (+6.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,618,442
Open 1.240
Bid (Size) 1.280 (500)
Ask (Size) 1.310 (8,900)
Prev. Close 1.230
Today's Range 1.210 - 1.340
52wk Range 0.7362 - 2.610
Shares Outstanding 140,759,276
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron (HRTX) Q4 2025 Earnings Call Transcript ↗
Heron (HRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+4.0%
+4.0%
1 Month
+61.6%
+61.6%
3 Month
-4.4%
-4.4%
6 Month
+14.9%
+14.9%
1 Year
-38.5%
-38.5%

More News

Read More
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlook ↗
Via Chartmill
News headline image
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
Via Benzinga
News headline image
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Mixed Q3 2025 Results, Misses Revenue and Earnings Estimates ↗
Via Chartmill
News headline image
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Heron (HRTX) Q2 Acute Care Jumps 56% ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
Via InvestorPlace

Frequently Asked Questions

Is Heron Therapeutics, Inc. - Common Stock publicly traded?
Yes, Heron Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Heron Therapeutics, Inc. - Common Stock trade on?
Heron Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Heron Therapeutics, Inc. - Common Stock?
The ticker symbol for Heron Therapeutics, Inc. - Common Stock is HRTX on the Nasdaq Stock Market
What is the current price of Heron Therapeutics, Inc. - Common Stock?
The current price of Heron Therapeutics, Inc. - Common Stock is 1.310
When was Heron Therapeutics, Inc. - Common Stock last traded?
The last trade of Heron Therapeutics, Inc. - Common Stock was at 05/06/26 04:00 PM ET
What is the market capitalization of Heron Therapeutics, Inc. - Common Stock?
The market capitalization of Heron Therapeutics, Inc. - Common Stock is 184.39M
How many shares of Heron Therapeutics, Inc. - Common Stock are outstanding?
Heron Therapeutics, Inc. - Common Stock has 184M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.